Retatrutide Australia 2026: Research Guide, Dosage, Cost & Where to Buy

Retatrutide (LY3437943), also referred to as "reta peptide" in research literature, is a synthetic 39-amino-acid peptide developed by Eli Lilly as a triple-receptor agonist acting simultaneously on GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This multi-pathway mechanism distinguishes it from earlier-generation compounds: semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP dual agonist).

In preclinical and clinical research, Retatrutide has attracted significant interest for its effects on metabolic regulation, appetite suppression, energy expenditure, and body weight. The addition of glucagon receptor agonism, absent in semaglutide and tirzepatide, drives thermogenesis and hepatic fat reduction through distinct mechanisms, making the tri-agonist profile a primary area of investigation.

A Phase 2 clinical trial published in The New England Journal of Medicine (Jastreboff et al., 2023) evaluated Retatrutide in adults with obesity over 48 weeks. Key findings:

• Mean body weight reduction at 12mg weekly: 24.2%, the largest reduction reported in any pharmacological weight-loss trial to date
• Dose-dependent response: 4mg cohort showed 8.7%, 8mg cohort showed 17.5% reductions
• Secondary outcomes: improvements in waist circumference, fasting glucose, triglycerides, and blood pressure
• Adverse event profile: predominantly nausea, vomiting, and GI effects, dose-dependent, most frequent during escalation phases

For context: semaglutide reported ~15% weight loss (STEP trials, 68 weeks); tirzepatide reported ~21% (SURMOUNT-1, 72 weeks). No direct head-to-head trial between these compounds has been completed.

Additional research areas under active investigation include NAFLD/NASH (glucagon receptor activation is associated with hepatic fat reduction), cardiometabolic risk markers, type 2 diabetes management, and energy expenditure pathways.

Retatrutide's pharmacological profile is defined by simultaneous agonism at three G-protein-coupled receptors, each contributing distinct metabolic effects:

Did You Know? The glucagon receptor component (GCGR) is the key differentiator. Glucagon agonism drives thermogenesis, increasing basal metabolic rate, and is associated with significant hepatic fat reduction in preclinical models. This is why Retatrutide is being studied for NAFLD/NASH endpoints in the TRIUMPH programme, not just weight loss.

Critically, Retatrutide's three-component activity is balanced so that glucagon-driven glycogenolysis (blood glucose increase) is offset by the GLP-1 and GIP components' insulinotropic actions. In Phase 2 data, fasting blood glucose actually improved across all dose cohorts despite GCGR agonism.

The Phase 2 NEJM 2023 trial tested escalating weekly dose arms over 48 weeks. Below are the key dose/outcome data from the published results (Jastreboff et al., 2023):

Dosing Note The Phase 2 protocol used a gradual dose escalation schedule to reduce GI adverse events during the induction phase. Doses were administered once weekly via subcutaneous injection, consistent with the once-weekly format used for semaglutide and tirzepatide. This titration approach is standard across GLP-1 class compounds.

A notable finding: the 8mg and 12mg cohorts showed near-identical responder rates (100% ≥5% weight loss) with only a 1.4% absolute difference in mean weight reduction. This suggests the dose-response curve approaches a plateau at the higher dose range, a pattern also observed with tirzepatide in SURMOUNT-1. Phase 3 TRIUMPH protocols are using dose ranges informed by Phase 2 safety and efficacy data.

The adverse event profile of Retatrutide in Phase 2 was consistent with the GLP-1 class, with a dose-dependent pattern. Most events occurred during dose escalation and attenuated with continued treatment at stable dose. Key adverse events by cohort from the NEJM 2023 data:

Key Finding: Heart Rate Phase 2 data showed a mean increase in resting heart rate of approximately 4–5 bpm across higher dose cohorts. This is attributed to the glucagon receptor component (GCGR agonism). Heart rate effects are one of the primary safety endpoints being monitored in the TRIUMPH cardiovascular outcomes trial (SYNERGY-OUTCOMES).

Discontinuation due to adverse events occurred in 7–16% of active treatment cohorts (versus 4% placebo), primarily due to GI events during dose escalation. No serious hepatic or renal adverse events were reported above background rates. The Phase 3 TRIUMPH programme is characterising the long-term safety profile, including cardiovascular endpoints, over a longer follow-up than the 48-week Phase 2 study permitted.

Retatrutide is not TGA-approved as a therapeutic medicine in Australia and is not available by prescription through standard pharmacy or compounding channels as of April 2026. The TGA issued an alert in April 2026 regarding unapproved GLP-1 and related peptides being supplied for therapeutic use without regulatory approval.

For laboratory research purposes, research-grade Retatrutide is available from Australian suppliers. OzPeps stocks Retatrutide in 20mg and 30mg vials for documented research use, see product pages for current availability and stock.

For researchers tracking the clinical pathway: the TRIUMPH Phase 3 programme (detailed below) is the key milestone before any Australian TGA regulatory submission. Australian clinical trial sites are currently active. Progress can be monitored via the Australian Clinical Trials Registry.

For the regulatory framework covering research peptides in Australia, see: Are peptides legal in Australia? →

The TRIUMPH programme is Eli Lilly's Phase 3 clinical development programme for Retatrutide, evaluating efficacy and safety across multiple disease endpoints beyond weight loss:

• SYNERGY-OUTCOMES, the programme's cardiovascular outcomes trial, investigating effects on major adverse cardiovascular events
• TRIUMPH kidney disease trial, evaluating Retatrutide's effect on renal function and chronic kidney disease progression
• TRIUMPH liver disease trial, targeting NAFLD/NASH endpoints, leveraging the glucagon receptor's hepatic mechanism

Australian research sites are participating in the TRIUMPH programme. Groups associated with the University of Sydney's Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders are among the active Australian investigators, the same institution involved in multiple GLP-1 class trials.

Phase 3 completion and subsequent FDA/TGA regulatory submission is expected in the 2026–2027 window, subject to trial timelines. Regulatory review following submission typically takes 12–18 months.

April 2026 note: The TGA alert on unapproved GLP-1 compounds applies to therapeutic supply channels and does not affect the TRIUMPH trial programme, which operates under clinical trial authorisation.

No direct head-to-head trial between Retatrutide and approved GLP-1 medications has been completed. The table below compares Phase 2/3 results from separate trials across different populations and timeframes.

The additional glucagon receptor component drives thermogenesis and hepatic fat reduction, mechanisms absent in semaglutide and tirzepatide. Whether this translates to meaningfully superior cardiovascular outcomes in Phase 3 is the central question the TRIUMPH programme is designed to answer.

See also: Retatrutide vs Tirzepatide: detailed comparison → · Semaglutide vs Tirzepatide vs Retatrutide →

A common question in metabolic research is how Retatrutide compares to tirzepatide (Mounjaro/Zepbound). The primary distinction is receptor profile:

• Tirzepatide: GLP-1 + GIP dual agonist
• Retatrutide: GLP-1 + GIP + glucagon triple agonist

The addition of glucagon receptor agonism in Retatrutide increases energy expenditure through thermogenesis, a mechanism not present in tirzepatide. Phase 2 data suggests this contributes to the larger weight reduction observed with Retatrutide relative to tirzepatide in comparable timeframes, though direct head-to-head trial data is not yet available.

For researchers studying energy balance and metabolic pathways, Retatrutide's tri-agonist profile offers a broader mechanistic scope than dual-agonist compounds. For a full breakdown: Retatrutide vs Tirzepatide deep dive →

For researchers planning a longitudinal study with Retatrutide, the Phase 2 trial provides the most detailed timeline reference. Results from the NEJM 2023 paper followed a structured four-phase protocol:

High-Responder Finding At week 48 (end of Phase 2), weight loss curves had not yet plateaued for a subset of participants in the 8mg and 12mg cohorts, suggesting continued response beyond the study window. This is a key rationale for the extended follow-up duration in the TRIUMPH Phase 3 programme.

The primary window for observable metabolic change (fasting glucose, triglycerides, waist circumference) in Phase 2 data was 8–24 weeks at stable dose. Secondary outcomes including blood pressure and liver enzyme markers relevant to NAFLD endpoints showed meaningful changes at 24 and 48 weeks. Blood pressure reductions of 6–9 mmHg systolic were observed across active cohorts.

Research-grade Retatrutide is priced per vial of lyophilised powder. Monthly cost depends on the vial size selected and the weekly dose protocol used in your research. The Phase 2 NEJM trial used weekly subcutaneous dosing from 1mg to 12mg; 8mg weekly is a commonly referenced protocol.

Monthly usage at common weekly dose protocols (using 4.33 weeks/month):

For current per-vial pricing: Retatrutide 20mg → · Retatrutide 30mg →. For a full monthly cost breakdown including bulk protocol pricing: full monthly cost breakdown →

Research-grade Retatrutide is supplied as a lyophilised (freeze-dried) powder in sealed vials. Common vial sizes available from Australian suppliers include:

• 10mg vials, the most common starting point for research protocols; reconstituted with 1–2mL bacteriostatic water, yielding a 5–10mg/mL solution
• 20mg vials, suitable for extended research timelines without mid-study reorder
• 30mg vials, bulk option; lower per-mg cost; requires careful storage once reconstituted

Lyophilised Retatrutide is stable at −20°C for 24+ months. Once reconstituted, the peptide solution should be stored at 2–8°C and used within 28–42 days, depending on storage conditions. Avoid repeated freeze-thaw cycles of reconstituted solution.

OzPeps stocks research-grade Retatrutide in 20mg and 30mg vials.

Retatrutide lyophilised powder must be reconstituted before use in research settings. Reconstitute and store research-grade vials following the standard protocol, see our peptide reconstitution & storage guide.

Compound-specific concentrations: a 10mg vial with 2mL bacteriostatic water = 5mg/mL (5,000mcg/mL); a 20mg vial with 2mL bacteriostatic water = 10mg/mL (10,000mcg/mL).

Use OzPeps' free reconstitution calculator to confirm volumes and concentrations for any vial size or target dose.

Is retatrutide available in Australia?

Not as a TGA-approved therapeutic medicine. Research-grade Retatrutide is available from Australian suppliers including OzPeps for documented laboratory research use. Prescription availability is subject to Phase 3 trial completion and TGA regulatory review.

When can I get retatrutide in Australia?

The TRIUMPH Phase 3 programme is ongoing as of 2026. FDA and TGA regulatory submission is expected following trial completion, anticipated in the 2026–2027 window. Prescription availability, if approved, would follow regulatory review, typically 12–18 months after submission.

How much does retatrutide cost per month in Australia?

At 8mg/week (a commonly referenced Phase 2 protocol), monthly usage is approximately 34mg, roughly 1.1 × 30mg vials. For current per-vial pricing, see the 30mg product page. For a full protocol cost breakdown: Retatrutide cost Australia guide.

Is retatrutide better than Ozempic?

Phase 2 trial data shows Retatrutide produced ~24.2% mean weight loss versus ~15% for semaglutide (Ozempic/Wegovy) in separate trials over different timeframes. Mechanistically, the addition of glucagon receptor agonism adds thermogenesis and hepatic fat reduction absent in semaglutide. No direct head-to-head trial has been completed, Phase 3 TRIUMPH cardiovascular outcome data will be more definitive.

Is retatrutide better than Mounjaro (tirzepatide)?

Phase 2 Retatrutide data (24.2% at 48 weeks) outperforms SURMOUNT-1 tirzepatide data (~21% at 72 weeks) from separate trials. Retatrutide adds glucagon receptor agonism absent in tirzepatide. No direct head-to-head data is available. See: Retatrutide vs Tirzepatide →

What are the risks of retatrutide?

Phase 2 data reported a dose-dependent adverse event profile consistent with GLP-1-class compounds: predominantly nausea, vomiting, diarrhoea, and constipation, most frequent during dose escalation. The TRIUMPH Phase 3 programme is characterising the full long-term safety and cardiovascular outcome profile.

Can I buy retatrutide in Australia?

Research-grade Retatrutide is available from Australian suppliers for laboratory research. OzPeps stocks 20mg and 30mg vials with Australia-wide shipping and COA documentation.

How does retatrutide work differently from Ozempic and Mounjaro?

Ozempic (semaglutide) targets GLP-1 receptors only. Mounjaro (tirzepatide) targets GLP-1 and GIP receptors. Retatrutide adds a third target, the glucagon receptor (GCGR), which drives thermogenesis (increased metabolic rate) and hepatic fat reduction. This tri-agonist profile is the mechanistic basis for Retatrutide's higher observed weight loss in Phase 2 versus either comparator in their respective trials.

Which GLP-1 peptide shows the most weight loss in trial data?

From published Phase 2/3 trial data: Retatrutide showed the highest mean weight loss (24.2% at 48 weeks), followed by tirzepatide (~21% at 72 weeks in SURMOUNT-1) and semaglutide (~15% at 68 weeks in STEP-1). These are separate trials with different populations and durations, direct head-to-head comparison data does not exist. For a full comparison: Semaglutide vs Tirzepatide vs Retatrutide →

Is retatrutide safe?

Phase 2 data showed a safety profile consistent with GLP-1-class compounds: predominantly nausea, vomiting, diarrhoea, and constipation, most frequent during dose escalation. A mean resting heart rate increase of ~4–5 bpm was noted at higher doses due to GCGR agonism. No serious hepatic or renal adverse events above background were reported. Long-term cardiovascular safety is being evaluated in the Phase 3 TRIUMPH SYNERGY-OUTCOMES trial, with results expected post-2026.

OzPeps supplies research-grade Retatrutide Australia-wide with Certificate of Analysis documentation, fast dispatch, and Express Post shipping. View current stock and pricing:

Retatrutide 20mg → · Retatrutide 30mg →

Related guide: Retatrutide monthly cost breakdown →

All Retatrutide products sold by OzPeps are supplied strictly for laboratory and in-vitro research purposes. They are not TGA-approved therapeutic goods, are not intended for human or animal consumption, and are not sold for diagnostic or treatment purposes. Researchers are responsible for compliance with all applicable regulations.